Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update GlobeNewswire - Tue Mar 4, 7:30AM CST

ADIL : 0.6778 (+4.28%)
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04 GlobeNewswire - Tue Feb 25, 8:00AM CST

ADIL : 0.6778 (+4.28%)
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies GlobeNewswire - Wed Feb 19, 8:00AM CST

ADIL : 0.6778 (+4.28%)
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders GlobeNewswire - Wed Feb 12, 8:00AM CST

ADIL : 0.6778 (+4.28%)
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder GlobeNewswire - Wed Jan 29, 8:00AM CST

ADIL : 0.6778 (+4.28%)
Adial Pharmaceuticals Secures Expanded Patent for Genotype-Based Treatment of Alcohol Use Disorder Quiver Quantitative, Inc. - Tue Dec 3, 2024

Adial Pharmaceuticals receives a patent for expanded genotype coverage in treating alcohol use disorder with its drug AD04.Quiver AI SummaryAdial Pharmaceuticals, a clinical-stage biopharmaceutical company...

ADIL : 0.6778 (+4.28%)
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations GlobeNewswire - Tue Dec 3, 2024

ADIL : 0.6778 (+4.28%)
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder GlobeNewswire - Thu Nov 14, 2024

ADIL : 0.6778 (+4.28%)
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update GlobeNewswire - Wed Nov 13, 2024

ADIL : 0.6778 (+4.28%)
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer GlobeNewswire - Tue Nov 5, 2024

ADIL : 0.6778 (+4.28%)

Barchart Exclusives

This Defensive Tech Stock Could Be the Next Dividend Aristocrat. Is It a Buy Now? Barchart - Tue Apr 22, 6:30PM CDT
Microsoft has the highest dividend yield among its Magnificent 7 peers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot